For a deeper look at GLP-1 and next-generation metabolic peptide mechanisms, explore our Research Library
Most metabolic peptide research over the past decade has been built around a single receptor target. GLP-1 agonists demonstrated that engaging appetite-regulating pathways could produce meaningful metabolic change. Dual agonists like tirzepatide added GIP receptor engagement and pushed outcomes further. Retatrutide, the research compound also known as Reta, takes the next step, targeting GIP, GLP-1, and glucagon receptors simultaneously in a single molecule. That third receptor is what changes the equation.
The Phase 2 obesity trial published in the New England Journal of Medicine in 2023 established the foundation. At the highest dose over 48 weeks, participants recorded up to 24.2% mean body weight reduction — a figure that outpaced every previously approved pharmacotherapy at the time. A parallel Phase 2 trial in people with type 2 diabetes, published in The Lancet the same year, showed 16.9% weight loss alongside HbA1c reductions of 2.2%, with 77 to 82% of participants reaching euglycemia. The glucagon receptor component is what sets this mechanism apart: it drives hepatic fat oxidation and increases energy expenditure through pathways that GLP-1 agonism alone cannot access.
A 2024 Phase 2a trial published in Nature Medicine added a striking data point. Retatrutide produced up to 82% reduction in liver fat in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) — a condition now affecting an estimated 38% of the global population. That positions retatrutide as a compound of significant research interest well beyond weight management, particularly for investigators studying the intersection of obesity, hepatic metabolism, and cardiometabolic risk. Researchers exploring this angle may find our GLP-1 & Metabolic Research section a useful reference point.
Phase 3 data is now arriving. Lilly’s TRIUMPH program, enrolling more than 5,800 participants across four global registrational trials, is evaluating retatrutide across obesity, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and MASLD. The first Phase 3 topline results, from TRIUMPH-4, showed average weight loss of up to 71.2 lbs alongside meaningful reduction in osteoarthritis pain, an outcome that signals retatrutide’s potential across multiple disease categories. Additional TRIUMPH readouts are expected throughout the coming year.
As of 2026, retatrutide remains an investigational compound and has not received regulatory approval for any indication. The research base is expanding rapidly, and Phase 3 data will determine whether it earns a place alongside approved metabolic therapies. BioStrata Research supplies Reta as a research-grade compound for laboratory use only. For researchers building out a metabolic peptide program, it represents the most mechanistically complete GLP receptor agonist currently under active investigation.
Retatrutide’s Phase 3 Results Are In — And They’re Reshaping the Metabolic Research Landscape
Peptides Go Mainstream — And Why Research Standards Matter More Than Ever